GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study
GLAUDIA
New Diagnostic Paradigms for the Identification of Early Glaucomatous Damage
1 other identifier
observational
60
0 countries
N/A
Brief Summary
This observational study aims to identify early diagnostic markers of glaucomatous damage by combining functional and structural assessments. Patients with primary open-angle glaucoma and ocular hypertension will undergo comprehensive ophthalmological evaluation, including visual field testing and multimodal imaging of the optic nerve and retina. Both retrospective and prospective data will be collected. The main objective is to define new diagnostic paradigms for detecting early glaucomatous changes and to improve the accuracy of current clinical practice in glaucoma management.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2025
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2025
CompletedStudy Start
First participant enrolled
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
October 7, 2025
September 1, 2025
2.2 years
September 29, 2025
September 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Prevalence of early glaucomatous damage detected by multimodal imaging
Evaluation of structural parameters from OCT and OCTA and functional indices from visual field testing to detect early glaucomatous damage in ocular hypertensive and glaucoma patients.
Baseline to 24 months
Secondary Outcomes (1)
Correlation between OCT structural parameters and visual field indices
Baseline to 24 months
Eligibility Criteria
Adult patients (40-90 years) with primary open-angle glaucoma, ocular hypertension, or healthy controls, recruited at the Glaucoma Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS.
You may qualify if:
- Age between 40 and 90 years.
- Best-corrected visual acuity ≥ 0.1 LogMAR (≥ 8/10).
- For primary open-angle glaucoma (POAG):
- IOP ≥ 21 mmHg with normal visual field and/or normal optic nerve head/RNFL, or
- Suspicious optic nerve head (excavation), or
- Reproducible glaucomatous visual field defect.
- POAG patients stratified by visual field mean deviation (MD): -3 to -10 dB (S1-S2 Brusini classification).
You may not qualify if:
- Best-corrected visual acuity worse than 0.1 LogMAR (\< 8/10).
- Ocular surgery in the last 6 months (except uncomplicated cataract extraction).
- Previous vitreoretinal surgery for macular pathologies (e.g., macular pucker, macular hole) or retinal detachment.
- High myopia (\> -3 diopters).
- Optic disc anomalies not attributable to glaucoma (tilted disc, papillary drusen, other morphological/functional anomalies).
- Severe motor disability preventing proper positioning for tests.
- Cognitive impairment reducing test reliability.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 29, 2025
First Posted
October 7, 2025
Study Start
October 1, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
June 1, 2028
Last Updated
October 7, 2025
Record last verified: 2025-09